Get the Stockscreener App
20.73
2.62%
2.7559
After Hours:
20.68
-0.0459
-0.22%
Defiance Trillion Dollar Club Index Etf stock is traded at $20.73, with a volume of 1,942.
It is up +2.62% in the last 24 hours and up +2.67% over the past month.
See More
Previous Close:
$17.97
Open:
$20.6
24h Volume:
1,942
Relative Volume:
66.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
33.43
EPS:
0.62
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+2.67%
6M Performance:
+137.32%
1Y Performance:
+6.04%
1-Day Range:
$20.59
$20.73
1-Week Range:
$20.59
$20.73
52-Week Range:
$20.59
$20.73
Defiance Trillion Dollar Club Index Etf Stock (TRIL) Company Profile
Name
Defiance Trillion Dollar Club Index Etf
Sector
Industry
Phone
-
Address
-
Compare TRIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRIL
Defiance Trillion Dollar Club Index Etf
|
20.73 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
337.43 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
685.24 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
688.60 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
260.08 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
628.09 | 124.43B | 0 | 0 | 0 | 0.00 |
Defiance Trillion Dollar Club Index Etf Stock (TRIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-14-21 | Initiated | The Benchmark Company | Buy |
| Oct-12-20 | Initiated | Evercore ISI | Outperform |
| Sep-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-17-20 | Initiated | Craig Hallum | Buy |
| Jun-19-20 | Initiated | Oppenheimer | Outperform |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Apr-13-18 | Resumed | Leerink Partners | Mkt Perform |
| Jul-17-17 | Initiated | H.C. Wainwright | Buy |
| Aug-03-16 | Initiated | Ladenburg Thalmann | Buy |
| May-15-15 | Initiated | Oppenheimer | Outperform |
| Apr-27-15 | Initiated | Leerink Partners | Outperform |
View All
Defiance Trillion Dollar Club Index Etf Stock (TRIL) Latest News
TRIL ETF Holdings List — BOATS:TRIL - TradingView
Defiance floats ETF tied to firms, digital assets valued above US$1 trillion - Structured Retail Products
TRIL Stock Fund Price and Chart — BOATS:TRIL - TradingView
US ETF launches from 25th September to 2nd October, 2025 - ETF Express
‘$1 Trillion Club’ ETF Offers Investors Exposure to Tech Giants and Bitcoin - The Currency analytics
A new "Trillion Dollar" ETF based on stocks and Bitcoin has appeared in the US. - Happy Coin News
'$1T Club' ETF offers exposure to tech giants and Bitcoin - Bitget
Tron Inc. Shares Tumble 85% From June Peak Amid DAT Market Slump - Decrypt
Defiance ETFs Launches New Trillion-Dollar Assets ETF: U.S. Access to Tech Giants and Crypto-Linked Plays - Blockchain News
SEC No-Action Letter Creates Opening for More Firms to Serve as Crypto Custodians - Decrypt
Ripple CTO David Schwartz to Step Back, Remain on Board as CTO Emeritus - Decrypt
'$1 Trillion Club' ETF Gives Investors Exposure to Tech Giants—And Bitcoin - Decrypt
Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New “Magnificent 7” of Global Markets - GlobeNewswire
TRIL ETF Analysis: Dividends, Returns NASDAQ:TRIL - TradingView
Defiance Launches JEDI – Drone & Modern Warfare ETF: Exposure to Leading Drone and Modern Warfare Companies - GlobeNewswire
Defiance ETFs Launches QLDY, the First ETF to Pay Distributions Twice Weekly * - GlobeNewswire
Defiance’s QTUM – Quantum Computing ETFSurpasses $2 - GlobeNewswire
Sezary Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | 4SC AG, Seagen Inc., Merck Sharp & Dohme Corp., Innate Pharma, Trillium Therapeutics, Sec - Barchart.com
Defiance ETFs Launches Leveraged + Income ETFs for AMD (AMDU) and Super Micro Computer (SMCC) - GlobeNewswire
Defiance ETFs Launches Leveraged + Income ETFs for Palantir - GlobeNewswire
Defiance Launches VIXI: Enhanced Long Volatility ETF with Leveraged Short S&P 500 Exposure - GlobeNewswire
How Many Trillium Therapeutics Inc. (TSE:TRIL) Shares Do Institutions Own? - ca.sports.yahoo.com
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape - Barchart.com
Relapsing Refractory Multiple Myeloma Pipeline Outlook Report 2025: Key 55+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn
Defiance Launches AIPO: The First ETF Focused on AI Power Infrastructure - GlobeNewswire
Weekly ETF Industry Recap: U.S., Europe, and Canada Highlights – July 7-July 11, 2025 - Trackinsight
Pfizer ends Phase 1b/2 trial for final Trillium CD47 drug - Endpoints News
Defiance ETFs Unveils $MST: The First Leveraged MicroStrategy ETF that Seeks to Pay Income Weekly - GlobeNewswire
PD-1 and PD-L1 Inhibitors Market Report- Expansive Coverage on the Profit Sources - openPR.com
CD47 Targeting Therapeutics Market Robust Expansion is expected to 2034 - openPR.com
Defiance Launches $GLDY, Gold Enhanced Options Income ETF - GlobeNewswire
Defiance’s XMAG ETF Outshines S&P 500 Amid “Magnificent 7” - GlobeNewswire
Defiance ETFs' QTUM, Quantum Computing ETF, Earns 5-Star Morningstar Rating and Surpasses $1 Billion in AUM - GlobeNewswire
CD47 Antigen Inhibitors Clinical Trial Pipeline Insights Featuring 20+ Companies | DelveInsight - GlobeNewswire
$QTUM, Defiance Quantum Computing ETF, Surpasses $1 Billion in AUM - GlobeNewswire
Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics - Reuters
Zentalis Pharmaceuticals Announces Executive Leadership - GlobeNewswire
Defiance Launches XMAG The First ETF Offering Exposure to the S&P 500 Excluding the “Magnificent 7” Tech Giants - GlobeNewswire
As a Billionaire Activist Takes a Stake, Is Now the Time to Buy Pfizer Stock? - The Globe and Mail
Defiance ETFs Announces Monthly Distributions on $QQQY - GlobeNewswire
Quell Therapeutics Appoints Experienced Biopharma Leader - GlobeNewswire
Genexine, EPD Biotherapeutics to merge for new protein degraders - BioWorld MedTech
Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline - Business Wire
Pension plans still AWOL as Canadian life-sciences venture capital firms re-up for latest funds - The Globe and Mail
Global Breast Cancer Drug Market for Growth, Projected to Reach USD 12,012.1 Million by 2033 at a 1.1% of CAGR - marketresearchblog.org
Bayer and Vividion Therapeutics to highlight advancing oncology portfolio at AACR 2024 Annual Meeting - Bayer
Defiance Trillion Dollar Club Index ETF (NASDAQ: TRIL)Share Price - intelligentinvestor.com.au
AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billion - The Globe and Mail
Chronic Myeloid Leukemia Treatment Market On A Growth - GlobeNewswire
Pfizer to acquire Trillium in $2.3bn deal - BioProcess International
Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment - PR Newswire
Defiance Trillion Dollar Club Index Etf Stock (TRIL) Financials Data
There is no financial data for Defiance Trillion Dollar Club Index Etf (TRIL). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):